JATT Acquisition (JATT) Competitors $1.03 -0.04 (-3.74%) As of 05/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JATT vs. MIST, EPIX, IOBT, JSPR, PDSB, TNYA, JMAC, PYXS, ELUT, and INCRShould you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Milestone Pharmaceuticals (MIST), ESSA Pharma (EPIX), IO Biotech (IOBT), Jasper Therapeutics (JSPR), PDS Biotechnology (PDSB), Tenaya Therapeutics (TNYA), Maxpro Capital Acquisition (JMAC), Pyxis Oncology (PYXS), Elutia (ELUT), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry. JATT Acquisition vs. Milestone Pharmaceuticals ESSA Pharma IO Biotech Jasper Therapeutics PDS Biotechnology Tenaya Therapeutics Maxpro Capital Acquisition Pyxis Oncology Elutia InterCure Milestone Pharmaceuticals (NASDAQ:MIST) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings. Is MIST or JATT more profitable? JATT Acquisition's return on equity of -49.58% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -151.82% -49.85% JATT Acquisition N/A -49.58%2.84% Do analysts recommend MIST or JATT? Milestone Pharmaceuticals presently has a consensus price target of $17.00, suggesting a potential upside of 1,131.88%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Milestone Pharmaceuticals is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, MIST or JATT? JATT Acquisition has lower revenue, but higher earnings than Milestone Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Pharmaceuticals$1M73.78-$59.69M-$0.78-1.77JATT AcquisitionN/AN/A$6.85MN/AN/A Do insiders and institutionals hold more shares of MIST or JATT? 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor MIST or JATT? In the previous week, Milestone Pharmaceuticals had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for Milestone Pharmaceuticals and 0 mentions for JATT Acquisition. Milestone Pharmaceuticals' average media sentiment score of 0.36 beat JATT Acquisition's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Milestone Pharmaceuticals Neutral JATT Acquisition Neutral Does the MarketBeat Community prefer MIST or JATT? Milestone Pharmaceuticals received 85 more outperform votes than JATT Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformMilestone PharmaceuticalsOutperform Votes8568.55% Underperform Votes3931.45% JATT AcquisitionN/AN/A SummaryMilestone Pharmaceuticals beats JATT Acquisition on 8 of the 12 factors compared between the two stocks. Get JATT Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JATT vs. The Competition Export to ExcelMetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$18.46M$2.93B$5.37B$19.42BDividend YieldN/A1.72%5.21%3.83%P/E RatioN/A30.5026.8234.23Price / SalesN/A400.15388.8534.85Price / Cash27.08168.6838.2517.51Price / Book-2.023.286.804.69Net Income$6.85M-$72.17M$3.23B$1.02B7 Day Performance-8.55%2.96%1.53%-1.74%1 Month Performance-21.90%3.25%10.05%7.46%1 Year Performance-80.55%-28.29%16.76%3.96% JATT Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JATTJATT AcquisitionN/A$1.03-3.7%N/A-82.1%$17.77MN/A0.003High Trading VolumeMISTMilestone Pharmaceuticals2.6772 of 5 stars$1.38-0.7%$17.00+1,131.9%-19.8%$73.78M$1M-1.7030News CoverageEPIXESSA Pharma2.005 of 5 stars$1.66+0.6%$2.00+20.5%-73.2%$73.69MN/A-2.4150Positive NewsIOBTIO Biotech3.0602 of 5 stars$1.11+7.8%$9.33+740.8%-17.8%$73.13MN/A-0.8130Analyst RevisionJSPRJasper Therapeutics2.1592 of 5 stars$4.82-4.4%$62.22+1,190.9%-79.1%$72.41MN/A-1.0220PDSBPDS Biotechnology1.5951 of 5 stars$1.58-3.1%$9.00+469.6%-55.6%$72.22MN/A-1.3620Analyst RevisionTNYATenaya Therapeutics3.442 of 5 stars$0.44-7.1%$6.25+1,313.7%-89.4%$71.92MN/A-0.31110JMACMaxpro Capital AcquisitionN/A$5.33-1.4%N/A+1,580.3%$71.50MN/A0.002,021PYXSPyxis Oncology1.4278 of 5 stars$1.15-5.0%$9.00+682.6%-71.3%$71.24M$16.15M-1.1260Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionELUTElutia3.1759 of 5 stars$1.74-4.4%$8.00+359.8%-49.1%$70.88M$23.71M-0.67180Positive NewsINCRInterCure0.7349 of 5 stars$1.56-2.8%N/A-52.9%$70.87M$238.85M0.00350 Related Companies and Tools Related Companies MIST Alternatives EPIX Alternatives IOBT Alternatives JSPR Alternatives PDSB Alternatives TNYA Alternatives JMAC Alternatives PYXS Alternatives ELUT Alternatives INCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:JATT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JATT Acquisition Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share JATT Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
